Stock Analiz

Utah Medical Products Inc. UTMD

Medical/Dental Instruments · data as of November 13, 2026

$71.97Market cap $205M
Open the interactive analysis →

Utah Medical Products Inc. (UTMD) is a healthcare company listed in the US with a market value of about $205M. In the twelve months to September 30, 2026 it had revenue of $35M and net income of $11M, a net margin of 30.5%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is future growth (0/5).

Key numbers: a P/E of 21.5, a price to free cash flow of 18.9, 5-year revenue growth of -2% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 54% below the current price.

About Utah Medical Products

Utah Medical Products is listed in the US and classified in medical/dental instruments. Revenue went from $41M in 2014 to $39M in 2025, a decline of about 0.6% a year. It was profitable in 10 of the last 10 years in our data. Its share count fell by 11% over three years (buybacks). It spends 2% of revenue on research and development.

Score: 2.6 / 5

Value3/5
Future growth0/5
Track record1/5
Financial health5/5
Shareholder returns4/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Profitable 5 years in a row
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)21.5
Forward P/E—
P/FCF18.9
P/S5.9
P/B1.7
EV/EBITDA8.9
PEG6.28
Dividend yield1.75%
FCF yield5.3%
Shareholder yield5.8%
Intrinsic value vs. price−54%

Growth and quality

Revenue growth (1 yr)-5.8%
Revenue growth (5 yrs, per year)-1.8%
EPS growth (5 yrs, per year)3.4%
FCF growth (3 yrs, per year)-11.0%
Net margin (5-yr avg.)31.6%
ROIC (5-yr avg.)11.1%
Profitable years (of last 10)10
Years paying a dividend10

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$35M$39M$41M$50M$52M$49M$42M$47M$42M$41M$39M
Net income$11M$11M$14M$17M$16M$15M$11M$15M$19M$9M$12M
Free cash flow$11M$14M$15M$22M$20M$21M$19M$17M$16M$15M$11M
EPS (diluted)$3.34$3.48$3.96$4.57$4.52$4.04$2.94$3.94$4.95$2.28$3.22
Net margin30.5%29.3%33.9%33.1%31.5%30.1%25.6%31.4%44.2%20.5%30.9%
ROIC—7.6%9.5%10.8%13.8%13.6%10.4%14.3%20.0%19.2%17.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Utah Medical Products’s P/E ratio?

About 21.5, based on the last twelve months of diluted earnings per share.

Is Utah Medical Products stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 54% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Utah Medical Products pay a dividend?

Yes. The dividend yield is about 1.75%, and it has paid dividends for 10 years in our data.

Is Utah Medical Products a good stock to buy?

We do not give buy or sell advice. Utah Medical Products scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.